IRIS Accounts Production v25.1.4.42 12585612 Board of Directors 1.1.24 31.12.24 31.12.24 25.6.25 false true false false true false Auditors Opinion Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh125856122023-12-31125856122024-12-31125856122024-01-012024-12-31125856122022-12-31125856122023-01-012023-12-31125856122023-12-3112585612ns15:EnglandWales2024-01-012024-12-3112585612ns14:PoundSterling2024-01-012024-12-3112585612ns10:Director12024-01-012024-12-3112585612ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3112585612ns10:SmallEntities2024-01-012024-12-3112585612ns10:Audited2024-01-012024-12-3112585612ns10:SmallCompaniesRegimeForDirectorsReport2024-01-012024-12-3112585612ns10:SmallCompaniesRegimeForAccounts2024-01-012024-12-3112585612ns10:FullAccounts2024-01-012024-12-3112585612ns10:OrdinaryShareClass12024-01-012024-12-3112585612ns10:Director22024-01-012024-12-3112585612ns10:CompanySecretary12024-01-012024-12-3112585612ns10:RegisteredOffice2024-01-012024-12-3112585612ns5:CurrentFinancialInstruments2024-12-3112585612ns5:CurrentFinancialInstruments2023-12-3112585612ns5:ShareCapital2024-12-3112585612ns5:ShareCapital2023-12-3112585612ns5:RetainedEarningsAccumulatedLosses2024-12-3112585612ns5:RetainedEarningsAccumulatedLosses2023-12-3112585612ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3112585612ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-3112585612ns10:OrdinaryShareClass12024-12-3112585612ns5:RetainedEarningsAccumulatedLosses2023-12-3112585612ns5:RetainedEarningsAccumulatedLosses2024-01-012024-12-31
REGISTERED NUMBER: 12585612 (England and Wales)












Financial Statements

for the Year Ended 31 December 2024

for

Eumedica Pharma Ltd

Eumedica Pharma Ltd (Registered number: 12585612)






Contents of the Financial Statements
for the Year Ended 31 December 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


Eumedica Pharma Ltd

Company Information
for the Year Ended 31 December 2024







DIRECTORS: J A Merckx
M J Arnold





SECRETARY: MYUKOFFICE LTD





REGISTERED OFFICE: 8 Northumberland Avenue
London
WC2N 5BY





REGISTERED NUMBER: 12585612 (England and Wales)





AUDITORS: Try Lunn & Co
Chartered Accountants
and Statutory Auditors
Roland House
Princes Dock Street
HULL HU1 2LD

Eumedica Pharma Ltd (Registered number: 12585612)

Balance Sheet
31 December 2024

2024 2023
Notes £    £   
CURRENT ASSETS
Stocks 4,055,552 3,069,620
Debtors 4 1,168,717 1,678,471
Cash at bank 239,207 237,375
5,463,476 4,985,466
CREDITORS
Amounts falling due within one year 5 5,407,922 5,108,343
NET CURRENT ASSETS/(LIABILITIES) 55,554 (122,877 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

55,554

(122,877

)

CAPITAL AND RESERVES
Called up share capital 7 100 100
Retained earnings 8 55,454 (122,977 )
SHAREHOLDERS' FUNDS 55,554 (122,877 )

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 24 June 2025 and were signed on its behalf by:





J A Merckx - Director


Eumedica Pharma Ltd (Registered number: 12585612)

Notes to the Financial Statements
for the Year Ended 31 December 2024

1. STATUTORY INFORMATION

Eumedica Pharma Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The company is reliant on the financial support of Eumedica SA. The directors of Eumedica SA have agreed to provide continued financial support to ensure the company will be able to trade as a going concern for the foreseeable future.

Turnover
Sales are measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes, in respect of goods supplied during the year.

Sales are recognised on despatch of the goods in accordance with the company's terms of sale.

Stocks
Stocks are valued at cost, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Eumedica Pharma Ltd (Registered number: 12585612)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 7 (2023 - 5 ) .

4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 1,031,239 1,107,271
Other debtors 137,478 571,200
1,168,717 1,678,471

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade creditors 124,828 37,402
Amounts owed to group undertakings 4,083,929 3,560,515
Taxation and social security 451,350 426,476
Other creditors 747,815 1,083,950
5,407,922 5,108,343

6. SECURED DEBTS

The company uses KBC Commercial Finance NV invoice factoring. There is a fixed charge over book debts and proceeds of book debts.

7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
100 Ordinary £1 100 100

8. RESERVES
Retained
earnings
£   

At 1 January 2024 (122,977 )
Profit for the year 178,431
At 31 December 2024 55,454

Eumedica Pharma Ltd (Registered number: 12585612)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

9. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was qualified on the following basis:

Basis for qualified opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to the our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

During the course of our audit we have found evidence that shows that the valuation of closing stock contains an
impairment of £175,657 in relation to items of stock that are not valued correctly. In our opinion the Company should
make a provision for impairment of £175,657, decreasing the profit for the year and reducing the net assets at 31
December 2024 by that amount.

In addition, during our audit work on the opening balances, we have found evidence that shows that the opening
valuation of stock contains a potential impairment of £158,432 in relation to items of stock that are not valued
correctly. In our opinion the Company should have made a provision for impairment of £158,432 in the 31 December
2023 accounts, increasing the loss for the previous year and reducing the net assets as 31 December 2023 by that
amount. As a result of this, the profit in the 31 December 2024 accounts would be increased by this amount.

As the accounts have not been adjusted for the above the audit report is qualified on this basis.

Simon Moss FCCA (Senior Statutory Auditor)
for and on behalf of Try Lunn & Co

10. RELATED PARTY DISCLOSURES

The company is a wholly owned subsidiary of Eumedica SA, a company incorporated in Belgium.

During the year the company purchased goods to the value of £9,396,385 (2023: £6,787,753) from Eumedica SA, recharged sales commissions of £1,012,588 (2023: £881,777) and a distribution margin of £253,894 (2023: £222,590) to Eumedica SA, and incurred management fees totalling £180,000 (2023: £180,000) from Eumedica SA.

As at 31 December 2024 the company owed £4,083,929 (2023: £3,560,515) to Eumedica SA.

During the year the company purchased goods to the value of £228,967 (2023: £NIL) from Eumedica Pharmaceuticals AG, a company which is controlled by J Merckx. As at 31 December 2024 Eumedica Pharmaceuticals AG owed the company £7 (2023: £7).

11. ULTIMATE CONTROLLING PARTY

The ultimate controlling party is Mr Jacques Merckx.